Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Go back to Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment
(NASDAQ: EDSA) Delayed: 7.35 +0.47 (6.83%)
Previous Close $6.88    52 Week High
Open $6.94    52 Week Low
Day High $7.60    P/E N/A 
Day Low $6.56    EPS
Volume 258,619